Loading...
Loading...
SMMT| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | -0.0M |
| Operating Expense | 58.4M |
| Operating I/L | -58.1M |
| Other Income/Expense | 1.9M |
| Interest Income | 0.0M |
| Pretax | -56.3M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -56.3M |
Summit Therapeutics Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of medicines for infectious diseases in the United States and Latin America. The company's primary focus is on its lead product candidate, ridinilazole, an orally administered small molecule antibiotic currently in Phase III clinical trials for the treatment of Clostridioides difficile infection (CDI). Additionally, Summit Therapeutics offers SMT-738, designed to combat multidrug-resistant infections, particularly carbapenem-resistant Enterobacteriaceae infections, and the DDS-04 series for potential treatment of infections caused by the Enterobacteriaceae.
